The October 1 Cell study compares mitochondrial protein inventories across eight organisms. It combines experimental catalogues with computational predictions and highlights protein families present in pathogens but absent in humans. This is basic research, not a clinical treatment trial.

The public workflow uses mitochondrial isolation and mass spectrometry, then adds further evidence and a computational model. The distinction between a measured inventory and a prediction for another species matters: a list does not universally establish every protein's expected function.

Imagine a researcher seeking a point where a parasite can be damaged while human cells are spared. Rather than testing blindly, they obtain a shorter list for laboratory investigation. Our realistic application scenario is better experiment prioritization, not a ready-made infection pill.

No human counterpart does not automatically mean safety. Researchers must show that a candidate is essential to the parasite, can be targeted and does not harm the host through another mechanism. Dosing, delivery within the organism, resistance and potential clinical trials come later.

Our optimistic editorial horizon is 6–18 months for initial functional laboratory validation of a selected candidate, if a prepared team follows up. We cannot estimate time to human treatment. The near-term benefit may be fewer dead ends: research knows better where to spend its time, but still has to prove it is aiming correctly.